Clinical Trials Sponsored by Onyx Pharmaceuticals

Total 19553 results

Bayer
Onyx Therapeutics, Inc.

Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Neoplasms

Germany, France
Amgen
Onyx Therapeutics, Inc.

Completed

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

China
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Yale University
Onyx Therapeutics, Inc.

Completed

The Effect of Sorafenib on Portal Pressure

Clinically Significant Portal Hypertension

United States
ONY

Completed

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Respiratory Distress Syndrome

United States
Emory University
Onyx Therapeutics, Inc.

Terminated

Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
University Hospital, Toulouse
Celgene; Onyx Therapeutics, Inc.

Unknown

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction (IFM-CRd)

Multiple Myeloma

France
M.D. Anderson Cancer Center
Onyx Therapeutics, Inc.

Terminated

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Hackensack Meridian Health
Onyx Therapeutics, Inc.

Completed

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Waldenstrom Macroglobulinemia

United States
ONY

Suspended

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

Chronic Lung Disease | RDS of Prematurity | Surfactant Protein B Deficiency

United States
ONY

Terminated

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

Bronchiolitis

United States
Omnyx, LLC

Unknown

Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens (PrimeDx)

Primary Diagnosis of Surgical Pathology Specimens
AbbVie
Genentech, Inc; Onyx Therapeutics, Inc.

Active, not recruiting

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Multiple Myeloma

United States, Australia, Hungary, Puerto Rico, Spain
University of Arkansas
Onyx Therapeutics, Inc.

No longer available

UARK 2009-32 Compassionate Use Study of Carfilzomib (2009-32)

Multiple Myeloma

United States
ONY

No longer available

Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)

Neonatal Respiratory Distress

United States
M.D. Anderson Cancer Center
Onyx Therapeutics, Inc.

Completed

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Kidney Cancer

United States
Oryx GmbH & Co. KG

Completed

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)

Glioblastoma Multiforme

Germany
ONY
Avania

Not yet recruiting

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS (Aero-05)

Intubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)

United States
Memorial Sloan Kettering Cancer Center
Celgene; Onyx/Amgen

Active, not recruiting

High Dose Carfilzomib for Newly Diagnosed Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis; Onyx Therapeutics, Inc.

Completed

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Case Comprehensive Cancer Center
Bayer; Onyx Therapeutics, Inc.

Terminated

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Carcinoma, Hepatocellular

United States
Oryx GmbH & Co. KG

Completed

Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer (ParvOryx02)

Carcinoma, Pancreatic Ductal

Germany
Oryx GmbH & Co. KG

Completed

Vaccination Against MSI Colorectal Cancer

Colorectal Cancer

Germany
M.D. Anderson Cancer Center
Celgene; Onyx Therapeutics, Inc.

Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
Oryx GmbH & Co. KG

Completed

Immune Therapy of HPV-induced Cancers

HPV-induced Cancers

Germany
Weill Medical College of Cornell University
Onyx Therapeutics, Inc.

Active, not recruiting

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (CarBiRD)

Multiple Myeloma

United States
University of Michigan Rogel Cancer Center
Celgene; Onyx Therapeutics, Inc.

Completed

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Bayer/Onyx

Completed

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasms | Biphenotypic Leukemia | Infantile Leukemia (Both AML and ALL)

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Unknown

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Type 2 Diabetes Mellitus

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria

Clinical Trials Sponsored by Onyx Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations